



The Industry Expert in Gene
Synthesis Solutions



Blue Heron Biotech, LLC - a wholly owned subsidiary
of OriGene Technologies, Inc.
www.blueheronbio.com Bothell, WA USA



Using Synthesis to Build Multi-Site Libraries and Gene Variants to Improve Protein and Antibody Function

A Better Way to Discovery

Existing tools

New methods

New technologies

BlueHeron®

Founded in 1999 to automate labor-intensive reagent production by combining expertise in:

- Molecular biology
- Chemistry
- Informatics

2001 launched GeneMaker®

- Patented multi-technology platforms established
- Production scale custom gene synthesis services

2007-2010 Gold Standard Industry leader

- The first company to synthesize and deliver a 52KB gene
- The primary supplier for the 1st bacterial genome
- The sole DNA source for the 1st synthetic life by J. Craig Venter Inst.- 1 mega base of DNA synthesized in 1 month

2010 Joined OriGene as a wholly owned subsidiary



Goal: Efficient pathway to target discovery

Improve Protein Function

Improve Antibody Affinity

Discover New Targets

Site Saturation vs. Directed Evolution

doi:10.1016/j.jmb.2005.07.020

J. Mol. Biol. (2005) 352, 621–628

JMB

Available online at www.sciencedirect.com

SCIENCE @ DIRECT®




Site-saturation Mutagenesis is more Efficient than DNA Shuffling for the Directed Evolution of β -Fucosidase from β -Galactosidase




Monal R. Parikh and Ichiro Matsumura*

Evaluation of Beta-gal activity on a non-native substrate

- **Directed Evolution**
 - 7 iterated cycles of DNA shuffling and screening
 - 39-fold increase in non-native activity
 - 1,000-fold improved discrimination
- **Saturation Mutagenesis**
 - Saturated 3 residues in active site
 - H540V 225-fold higher activity on non-native
 - ~100,000-fold improved discrimination



Problem: What path to take?

Method	Roadblocks
• Random mutagenesis 	Inexpensive but low specificity Methods: error Prone PCR, MutS E. coli strains
• Recombination 	Need clones, limited by PCR, limit to mutation loci Method: PCR Shuffling (Stemmer, <i>et al.</i> Maxygen)
• Degenerate oligonucleotides 	Creates biased pools

Synthesis: A better option

New Option

- **Synthetic gene variants**
 - **Codon optimization**
 - **Simple base substitutions**
 - **Amino acid substitutions**
 - **Variable region substitutions**
 - **Defined Multi-site libraries**

Advantages

Can introduce changes
ANYWHERE

Enables ability to encode
specific changes (e.g. codon-
based)

Individual clones received in an
expression vector

Defined timeline and costs

Goal: Efficient pathway to target discovery

Improve Protein Function

Codon Optimization of Gene Sequence for Protein Expression

Submit:

Amino Acid Sequence

Include or exclude specific DNA motifs



Codon Optimization

Codon usage match

Expression Optimization

Secondary RNA structure
minimization

Goal: Efficient pathway to target discovery

Improve Antibody Affinity

Discover New Targets

Creating Variants

- **Simple Variants**
 - SNPs, adding new 5' or 3' tag or promoter
- **Complex Variants**
 - Multi-site base changes
 - Amino Acid scans and substitutions (R&D development)
- **Variants for Antibody Research**
 - Single Region Variable H/L chain single cassette
 - Dual Region Variable H/L chain swap
- **Variant Libraries- (R&D development)**
 - Complex Defined Variant Pooled Libraries
 - Multi-site, close proximity amino acid libraries
- **Dual Region swaps for antibody discovery**

Complex Variants

Multi-site base changes

ATGTCGAGATTCGATTAGAGCGCTCGAATCGATAGCTTAG



ATGTGGAGCTTCGATTAGAGCGCTCCAATCGITAGCTTAG

Varying methods for improving protein function/antibody affinity

- **Structure-based engineering**
 - Requires structure and highly detailed models of the proteins function
- **Mutagenesis and screening or selection**
 - Error-prone PCR
- **Directed Evolution**
 - Mix diversity from a family of native proteins
- **Synthetic Defined Multi-site Libraries**

Antibody Improvement

PEDS Advance Access published May 13, 2008

Protein Engineering, Design & Selection pp. 1–11, 2008
doi: 10.1093/protein/gzn027

Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases

J. Rogers^{1†}, R.J. Schoepp², O. Schröder^{1†},
T.L. Clements², T.F. Holland^{1†}, J.Q. Li^{1†}, J. Li^{1†},
L.M. Lewis^{1†}, R.P. Dirmeier¹, G.J. Frey^{1†}, X. Tan¹,
K. Wong^{1†}, G. Woodnutt^{1†}, M. Keller^{1†}, D.S. Reed³,
B.E. Kimmel^{1†} and E.C. Tozer^{1,4}

Traditionally, protection from pathogens can be achieved by either active or passive immunization. Active immunization in which a vaccine is administered to elicit a protective immune response is generally the desired therapeutic goal. Unfortunately, vaccine development can be slow and expens-

- Site saturation mutagenesis of 67 light and heavy chain CDR amino acids = ~1,350 clones
- Multi-site library with five best variants
- Best multi-site clone had two changes,
 - 40-fold higher affinity
 - Neutralized at an 8-fold lower concentration of antibody

Amino Acid Substitutions

- **Non-complex**

MTGPAGCTPTLLACPCGSCULCSLTPATRLCSTLPACGGPLGC

Amino Acid Substitution: Alanine → Cysteine

- **Moderately-Complex**

MTGPAGCTPTLLACPCGSCULCSLTPATRLCSTLPACGGPLGC

Replace each with given number of amino acids (19, 10, 5, etc.)

- **Complex-** R&D Technology Development

MTGPAVCTPTLLACPCGSCULCSLTPATRLCSTLPACGGPLGC

SINGLE REGION VARIANTS

Fast and economical antibody optimization and design

Figure 1: Define/Design the Variable Region

- Modify amino acid sequence
- Modify nucleotide sequence
- Scalable Projects make a few to hundreds of variants

Figure 2: Newly Synthesized Plasmid

- New Variable Regions will be inserted as requested to form the final plasmid ready for expression or screening
- Backbone vector can be a Customer-provided expression vector
- Delivered as individual, sequence verified clones

Applications:

- Antibody Screening
- Variant Screening

Benefits:

- Design Freedom
- Economical Solution
- Fast Turnaround

Figure 1:





Figure 2:



Your variants in the New Vector containing constant region(s)

BlueHeron® Biotech- Synthesis Application: Multi-site Defined Mutagenesis

Figure 1:

Choose the Amino Acid positions to replace or choose full saturation

Figure 2/3:

Each amino acid will be replaced synthetically

Delivered as individual, sequence verified clones or pooled groups

Advantages:

- Define 1 to 19 amino acids at single or multiple positions
- Sequence verified as individual clones
- Equal representation as pooled groups
- Ability to further define position changes downstream using an existing template for synthesis
- Fast (4-6 weeks)
- Economical

Figure 1: Wild Type



Figure 2: Single amino acid changes



Figure 3: Multiple amino acid changes per location:

ASAKVSCKASGYTFTCSVTAAPQVSAAVSTTLVLQP
 ASLKVSCKASGYTFTCLVTAAPQVSAAVSTLLVLQP
 ASCKVSCKASGYTFTCCVTAAPQVSAAVSTCLVLQP
 ASGKVSCKASGYTFTCGVTAAPQVSAAVSTGLVLQP
 ASKKVSCKASGYTFTCKVTAAPQVSAAVSTTKVLQP
 ASTKVSCKASGYTFTCIVTAAPQVSAAVSTTIVLQP

.
.
.

Dual Region Swaps

- Codon Optimize synthesized fragments.

- Synthesize with linkers, tags, promoter regions.

- Assemble in various configurations

- Blue Heron Bio adds synthetic ends to allow for cassette assembly


- Clone into customer-provided vector or BHB standard vector

- Delivered as individual clones- sequence verified

Parts- Synthesized individually



Fragments assembled in various configurations



Defined Multi-site Libraries

- Choose 50-300 amino acid positions in your protein
- Blue Heron delivers a library: 16-19 clones for each position
 - Customer defines number of amino acid or codon substitutions at each position
 - Example- 950 clones for a 50 position library
- Each is cloned and sequence-verified

Advantages of Using synthesis to create a multi-site library

- **Minimize the number of assays**
 - No need for 10X coverage to ensure that you assay each variant once
- **Maximize the value of the information**
 - Assay in triplicate
- **Optimize the time to results**
 - High quality clones + reproducible assays = high quality data

Timeline to Protein Improvement

	Blue Heron	Customer
Defined Saturation Mutagenesis	6-8 weeks	
Perform Assays, analyze data		2-4 weeks
Multi-Site Library	4-6 weeks	
Assay, choose best protein		2-4 weeks

- Improved protein in 3-5 months
- Predictable cost and well-defined results

Well-Defined Path to Improvement

- Small and well-defined number of highly-informative assays
- Crisp decision points
 - Single change improves the activity?
 - Multi-site results positive?
- Predictable costs and timeline
- If a protein is worth your scientists' time and effort, isn't it worth doing the definitive experiment?

- Services
- Knowledge Center
- News and Events
- About Us
- Contact Us

I want to fast-track my projects with one trusted provider.



The Gold Standard in Gene Synthesis.

Since 1999, Blue Heron has delivered tens of millions of base pairs of perfectly accurate genes to thousands of customers worldwide using its proprietary GeneMaker® multi-technology platform. Blue Heron continues to innovate with breakthrough technologies to meet the growing genes synthesis demands of researchers everywhere.

Sign Up For Blue Heron Webinar, Feb 16th, 2011



Whether you need one gene or one thousand, the simplest sequence or comprehensive codon substitutions across hundreds of regions, Blue Heron can deliver. Beyond any other synthesis provider, Blue Heron provides an unmatched level of service and attention to detail to give you the assurance that your project will be delivered as ordered, on time, and with no surprises. Blue Heron is the only choice when you need a gene synthesis partner — not just a gene synthesis vendor.

As of August, 2010, Blue Heron became a wholly owned subsidiary of OriGene Technologies, Inc. Combining OriGene's complete collection of human cDNA clones with Blue Heron's gene synthesis capacity, we can provide a whole product solution for the molecular biology research community. We are 100% committed to serving our customers with high quality, strict confidentiality standards, and improved business efficiency. [Learn More](#).



News
Rockville, MD – Aug 12th, 2010 – OriGene Technologies, Inc., announces the acquisition of Blue Heron Biotechnology.
NIH Taps Blue Heron to Help Combat Swine Flu Threat
Blue Heron Primary Supplier for First Synthetic Bacterial Genome



Lab News
Customers highlight Blue Heron advantages
Blue Heron contributes to key research



Knowledge Center
Antibody Engineering to Increase Affinity
Protein expression in mammalian cells
Expression vectors and PrecisionShuttle system